Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis Rydapt wins...

    Novartis Rydapt wins EU approval for AML, other diseases

    Written by Ruby Khatun Khatun Published On 2017-09-22T09:57:09+05:30  |  Updated On 18 Aug 2021 2:43 PM IST

    ZURICH: Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.


    Rydapt was cleared to be used along with chemotherapy to treat adults newly diagnosed with AML who have a specific genetic mutation called FLT3, Novartis said.


    The drug was also approved for three types of advanced systemic mastocytosis (ASM), a rare disease where mast cells accumulate in the skin, bone marrow, and some internal organs.


    AML is cancer that originates in the bone marrow and progresses rapidly, resulting in an abnormal increase in white blood cells. Rydapt, among Novartis's stable of potential $1 billion-per-year medicines, is targeted at those with a tough-to-treat form of the disease whose options have been limited.


    "For patients with FLT3-mutated AML, there have been no meaningful advancements in more than 25 years and with Rydapt they now have a targeted medicine that could significantly extend their lives," said Bruno Strigini, head of Novartis's cancer drugs business.


    Using Rydapt for FLT3-mutated AML patients resulted in a 23 percent reduction in the risk of death, Novartis has said.


    After its U.S. approval, analysts expect the drug will also find immediate uptake in Europe.


    "We expect high penetration rates as well as high prices because the disease is very serious and there is no competition," said Michael Nawrath, a Zuercher Kantonalbank analyst, in a note to investors.


    Nawrath forecasts $1.1 billion in annual sales in 2025.


    Novartis did not immediately give European pricing details.


    In the United States, Rydapt's list price for AML patients is $7,495 for a 14-day treatment and $14,990 for a 28-day treatment. In a late-stage trial on AML patients, the median duration of therapy was 42 days, implying a list price of $22,485.


    For ASM patients, the U.S. list price is $32,121 for a 30-day treatment duration, with the median duration of therapy in Novartis's clinical trials of 11.4 months.


    Novartis is continuing to study Rydapt in a late-stage trial in patients with AML without an FLT3 mutation, which could result in its expanded use.




    (Reporting by John Miller; editing by John Revill and Jason Neely)



    acute myeloid leukemiaadvanced systemic mastocytosisAMLapprovalcancerEUEuropean UnionFLT3-mutatedgenetic mutationMichael NawrathNovartisrare diseasesRydaptwins
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok